According to paperwork filed within the U.S. District Court, Northern District of New York, 24-year-old Shaquil Byrd started to expertise extreme breast progress inside months of initiating remedy with Risperdal on the age of 9. His grievance accused Johnson & Johnson and its Janssen Pharmaceuticals subsidiary of failing to offer docs and sufferers with enough warnings relating to this potential aspect impact.
On September 27th, the jury listening to Byrd’s case discovered that he had confirmed his failure-to-warn declare and awarded him $500,000 for previous and/or current ache and struggling, in addition to a further $500,000 for future ache and struggling. (Case No. 1:14-cv-00820)
“We are pleased that yet another gynecomastia plaintiff has prevailed in a Risperdal lawsuit. Our Firm is representing a number of other young men who also claim the medication caused their excessive breast development. We will continue to monitor this litigation for any developments that could impact our clients’ cases,” stated Sandy A. Liebhard, a companion at Bernstein Liebhard LLP, a nationwide regulation agency representing the victims of faulty medicine and medical units. The Firm continues to offer free authorized critiques to males and boys who have been recognized with gynecomastia allegedly associated to their use of Risperdal.
Risperdal Gynecomastia Litigation
Risperdal is an atypical antipsychotic medicine indicated to be used in grownup and adolescent sufferers with schizophrenia, adults and youngsters ages 10-to-17 with bipolar dysfunction, and youngsters (5-to-16 years of age) with autistic dysfunction. The drug was initially delivered to market in 1993. However, its first pediatric indications weren’t permitted by the FDA till October 2006.
The Risperdal label was additionally up to date in October 2006 to state that 2.three% of male adolescents handled with the drug had developed gynecomastia. Previously, the label had characterised the situation as a uncommon aspect impact that had been seen in fewer than 1 in 1,000 sufferers.
Shaquil Byrd’s lawsuit was the primary Risperdal gynecomastia case tried outdoors of the Pennsylvania Court of Common Pleas in Philadelphia, the place greater than 6,000 instances have been centralized in a mass tort program. The Pennsylvania litigation has been making an attempt gynecomastia instances since February 2015, with 4 juries awarding plaintiffs damages starting from $500,000 to $70 million. The defendants have additionally prevailed in a number of instances, whereas a quantity of Risperdal lawsuits have settled out of courtroom simply previous to trial. (Case No. 130600861)
Bernstein Liebhard LLP continues to offer free authorized evaluations to alleged victims of Risperdal and gynecomastia. To learn more about submitting a Risperdal lawsuit, please contact Bernstein Liebhard LLP by visiting the Firm’s web site, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based regulation agency solely representing injured individuals in complicated particular person and sophistication motion lawsuits nationwide since 1993. As a nationwide regulation agency, Bernstein Liebhard LLP possesses all of the authorized and monetary assets required to efficiently problem billion greenback pharmaceutical and medical system corporations. As a end result, our attorneys and authorized employees have been capable of get well greater than $three.5 billion on behalf of our shoppers. Bernstein Liebhard LLP is honored to as soon as once more be named to The National Law Journal’s “Plaintiffs’ Hot List,” recognizing the highest plaintiffs companies within the nation. This yr’s nomination marks the thirteenth yr the agency has been named to this prestigious annual record.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The regulation agency liable for this commercial is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior outcomes don’t assure or predict an identical end result with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
View unique content material:http://www.prnewswire.com/news-releases/risperdal-lawsuit-plaintiff-awarded-1-million-in-first-gynecomastia-trial-convened-outside-of-pennsylvania-bernstein-liebhard-llp-reports-300532582.html
SOURCE Bernstein Liebhard LLP